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Rationale: Most patients with COPD are managed by primary care physicians with little known about 
their management or variability in patient characteristics across healthcare systems in real life. Our 
aim was to compare the demographic and clinical characteristics of COPD patients managed in five 
large primary care medical groups in the U.S. 
Methods: This is an observational, patient registry study using data from the COPD Optimum Patient 
Care DARTNet Research Database (COPD-RD) from which the Advancing the Patient Experience (APEX) 
COPD registry is derived. The APEX in COPD registry collects, integrates, and standardizes 
retrospective and prospective primary care electronic health record (EHR) data and patient-reported 
information/outcomes, and plans to include 3,000 COPD patients. COPD patients included in the 
registry are ≥35 years old at diagnosis, with a COPD diagnosis code [ICD9CM, ICD10CM]. Baseline 
demographic and clinical EHR data were collected (Dec 2019-Jan 2020) from sites located in TX, OH, 
CO, NY and NC. Most data extend back as far as 2009. 
Results: A total of 17,192 patients with COPD, available for screening were included in this baseline 
analysis: TX (n=811), OH (n=8,722), CO (n=472), NY (n=1,149) and NC (n=6,038). The majority of 
patients at each site were female (>54%), over-weight/obese (>60%), and had a high co-morbidity 
burden, with hypertension predominating (>60%). Some inter-site variability was noted in terms of 
age, race/ethnicity, exacerbation frequency, treatment pattern and co-morbidity prevalence (Table). 
The TX site had the greatest prevalence of Hispanic patients, ICS/LABA use and diabetes mellitus, and 
relatively high rates of depression and asthma. The OH site was characterized by a large Black COPD 
patient population, highest prescription rates for ICS/LABA/LAMA, and greatest prevalence of GERD 
and OSA. CO site patients were predominantly white, experienced the fewest exacerbations and had 
the greatest prevalence of depression. The NY site COPD patients were predominantly Black and 
Hispanic, experienced most exacerbations, had the greatest ICS use, relatively high ICS/LABA/LAMA 
use, and had the greatest prevalence of hypertension, osteoarthritis, and asthma. Patients from the 
NC site tended to be older, had the lowest co-morbidity burden, and a treatment pattern 
characterized by high LABA/LAMA and ICS/LABA use, and relatively high rates of ICS/LABA/LAMA use. 
Conclusion: These data show the heterogeneity in demographic and clinical characteristics of patients 
diagnosed with COPD who are managed in primary care in the U.S.  
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Mean age (SD) 69.6 (11.8) 65.8 (10.9) 69.8 (12.9) 61.6 (10.8) 70.2 (10.8) 
Race/ethnicity N=725 N=8,617 N=365 N=903 N=4,606 
 Caucasian, n (%) 355 (43.8) 5,075 (58.2) 346 (73.3) 101 (8.8) 3,855 (63.8) 
 Black, n (%) 25 (3.1) 2,746 (31.5) 0 (0.0) 476 (40.6) 366 (6.1) 
 Hispanic, n (%) 333 (45.9) 704 (8.2) 16 (4.4) 329 (36.4) 362 (7.9) 
Exacerbations last 12 m      
 0, n (%) 473 (58.3) 5,044 (57.8) 308 (65.3) 670 (58.3) 4,118 (58.2) 
 1, n (%) 245 (30.2) 2,089 (24.0) 139 (29.4) 266 (23.2) 1,088 (18.0) 
 2, n (%) 71 (8.8) 818 (9.4) 18 (3.8) 91 (7.9) 445 (7.4) 
 3+, n (%) 22 (2.7) 771 (8.8) 7 (1.5) 122 (10.3) 387 (6.4) 
Treatment      
 LAMA 100 (12.3) 1,055 (12.1) 37 (7.8) 137 (11.9) 798 (13.2) 
 LABA/LAMA 64 (7.9) 987 (11.3) 25 (5.3) 158 (13.8) 1,031 (17.1) 
 ICS 11 (1.4) 365 (4.2) 61 (12.9) 288 (25.1) 254 (4.2) 
 ICS/LABA 370 (45.6) 2,404 (27.6) 123 (26.1) 201 (17.5) 1,872 (31.0) 
 ICS/LABA/LAMA 141 (17.4) 2,870 (32.9) 22 (4.7) 251 (21.8) 1,374 (22.8) 
Co-morbidities      
 Hypertension, n (%) 666 (82.1) 6,786 (77.8) 354 (75.0) 1,010 (87.9) 3,672 (60.8) 
 DM, n (%) 529 (65.2) 4,748 (54.4) 137 (29.0) 461 (40.1) 1,849 (30.6) 
 Depression, n (%) 471 (58.1) 4,211 (48.3) 410 (86.9) 618 (53.8) 1,530 (25.3) 
 Anxiety, n (%) 307 (37.9) 3,355 (38.5) 163 (34.5) 337 (29.3) 1,241 (20.6) 
 OA, n (%) 327 (40.3) 4,546 (52.1) 161 (34.1) 688 (59.9) 1,376 (22.8) 
 GERD, n (%) 281 (34.6) 4,244 (48.7) 179 (37.9) 486 (42.3) 1,568 (26.0) 
 OSA, n (%) 239 (29.5) 4,116 (47.2) 163 (34.5) 90 (7.8) 1,687 (27.9) 
 Asthma, n (%) 325 (40.1) 3,387 (38.8) 128 (27.1) 708 (61.6) 1,165 (19.3) 
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